Ch Biotech R And D Co
Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
DitchCarbon Score
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ch Biotech R And D Co's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ch Biotech R And D Co's reported carbon emissions
In 2022, CH Biotech R&D Co., headquartered in Taiwan (TW), reported total carbon emissions of approximately 4,000,000 kg CO2e. This figure includes 437,910 kg CO2e from Scope 1 emissions, 3,260,880 kg CO2e from Scope 2 emissions, and 140,920 kg CO2e from Scope 3 emissions. Compared to 2021, where emissions were about 4,000,000 kg CO2e as well, the company has maintained a consistent emissions profile. The breakdown for 2021 shows Scope 1 emissions at 444,390 kg CO2e, Scope 2 at 3,458,040 kg CO2e, and Scope 3 at 92,920 kg CO2e. This indicates a slight reduction in Scope 1 emissions and a notable decrease in Scope 3 emissions from 2021 to 2022. Currently, CH Biotech R&D Co. has not set specific reduction targets or climate pledges, nor do they have any initiatives reported under the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from any parent organization, indicating that all reported figures are directly from CH Biotech R&D Co., Ltd. Overall, while CH Biotech R&D Co. has shown stability in its emissions, the absence of formal reduction targets suggests an opportunity for enhanced climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 444,390 | 000,000 |
| Scope 2 | 3,458,040 | 0,000,000 |
| Scope 3 | 92,920 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ch Biotech R And D Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
